ReviewActa pharmacologica Sinica2014
Microvesicles and diabetic complications--novel mediators, potential biomarkers and therapeutic targets.
Review in Acta pharmacologica Sinica, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed.
- Extracellular Vesicles Link Cerebral Ischemia to Coronary Microvascular Dysfunction - Role for RGD Motif-Activated Endothelin Signaling.Journal of cardiovascular translational research · 2026Article
- Obesity and Adipose-Derived Extracellular Vesicles: Implications for Metabolic Regulation and Disease.Biomolecules · 2025Review
- The Role of Exercise in Regulating the Generation of Extracellular Vesicles in Cardiovascular Diseases.Reviews in cardiovascular medicine · 2024Review
- Circulating extracellular microvesicles associated with electronic cigarette use increase endothelial cell inflammation and reduce nitric oxide production.Experimental physiology · 2024Article
- EVs-miR-17-5p attenuates the osteogenic differentiation of vascular smooth muscle cells potentially via inhibition of TGF-β signaling under high glucose conditions.Scientific reports · 2024Article
- Extracellular vesicles in atherothrombosis: From biomarkers and precision medicine to therapeutic targets.Immunological reviews · 2022Review
- Platelets and Their Role in Hemostasis and Thrombosis-From Physiology to Pathophysiology and Therapeutic Implications.International journal of molecular sciences · 2022Review
- Review
- Microparticles in systemic sclerosis, targets or tools to control fibrosis: This is the question!Journal of scleroderma and related disorders · 2020Review
- Current understanding of the role of Adipose-derived Extracellular Vesicles in Metabolic Homeostasis and Diseases: Communication from the distance between cells/tissues.Theranostics · 2020Review
- Exosome and Biomimetic Nanoparticle Therapies for Cardiac Regenerative Medicine.Current stem cell research & therapy · 2020Review
- Relationship between circulating microparticles and hypertension and other cardiac disease biomarkers in the elderly.BMC cardiovascular disorders · 2019Article
- Platelet microparticles contribute to aortic vascular endothelial injury in diabetes via the mTORC1 pathway.Acta pharmacologica Sinica · 2019Article
- Dysfunction of Mesenchymal Stem Cells Isolated from Metabolic Syndrome and Type 2 Diabetic Patients as Result of Oxidative Stress and Autophagy may Limit Their Potential Therapeutic Use.Stem cell reviews and reports · 2018Review
- The biology of extracellular microvesicles.Traffic (Copenhagen, Denmark) · 2018Review
- Microvesicles as Emerging Biomarkers and Therapeutic Targets in Cardiometabolic Diseases.Genomics, proteomics & bioinformatics · 2018Review
- Podocyte-derived microparticles promote proximal tubule fibrotic signaling via p38 MAPK and CD36.Journal of extracellular vesicles · 2018Article
- Pathogenic roles of microvesicles in diabetic retinopathy.Acta pharmacologica Sinica · 2018Review
- Endothelial- and Immune Cell-Derived Extracellular Vesicles in the Regulation of Cardiovascular Health and Disease.JACC. Basic to translational science · 2017Review
- Circulating microparticles in acute diabetic Charcot foot exhibit a high content of inflammatory cytokines, and support monocyte-to-osteoclast cell induction.Scientific reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Microvesicles (MVs), also known as microparticles, are small membrane vesicles released from different cell types under different conditions. MVs have been detected in the circulation and in organs/tissues in various diseases, including diabetes. Patients with different types of diabetes and complications have different cellular MV patterns. Studies have shown that MVs may mediate vascular thrombosis, vascular inflammation, angiogenesis, and other pathological processes of the disease through their procoagulant, pro-inflammatory, pro-angiogenic, proteolytic, and other properties. Therefore, MVs contribute to the development of diabetic macrovascular and microvascular complications. In addition, clinical studies have indicated that changes in MV number and composition may reflect the pathophysiological conditions of disease, and therefore, may serve as potential biomarkers for diagnostic and prognostic use. Understanding MVs' involvement in the pathophysiological conditions may provide insight into disease mechanisms and would also be helpful for the development of novel therapeutic strategies in the future. Here, we review the latest publications from our group and other groups and focus on the involvement of MVs in diabetic complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.